Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bronchiectasis

Bronchiectasis

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bronchiectasis

20 trials tracked for Bronchiectasis: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 189 citations.

20Trials tracked
7Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 6 Other / NA 7
  1. Phase 3 Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed · 189 cited
  2. Phase 3 Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed · 187 cited
  3. Phase 3 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis Completed · 170 cited
  4. Phase 4 Efficacy of Azithromycin in Treatment of Bronchiectasis Completed
  5. Phase 3 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed
  6. Phase 3 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed
Show 14 more trials
  1. Phase 3 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed
  2. Phase 2 A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis Completed
  3. Phase 2 Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis Completed
  4. Phase 2 A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) Completed
  5. Phase 2 Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa. Completed
  6. Phase 2 Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis Completed
  7. Phase 2 Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis Completed
  8. N/A Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis Completed
  9. N/A Effect of HFCWO Vests on Spirometry Measurements Completed
  10. N/A Assessment of an Exhaled Breath Test to Detect Bronchiectasis Completed
  11. N/A Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability Completed
  12. N/A Effects of Inspiratory Muscle Training in Patients With Bronchiectasis Completed
  13. N/A Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation Completed
  14. N/A Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Bronchiectasis: what the trials found

Azithromycin treatment demonstrated statistically significant improvements in several clinical markers, including a reduction in 24-hour sputum volume (p<0.01), improved health status as measured by the St George's Respiratory Questionnaire score (p<0.01), and maintained spirometry values (FEV1) (p<0.01) 1.

Inhaled mannitol was associated with a statistically significant improvement in quality of life scores (SGRQ) compared to placebo (p=0.0457), although it did not significantly impact the rate of graded pulmonary exacerbations or the amount of antibiotics prescribed for treated exacerbations 4.

AZLI showed a statistically significant improvement in respiratory symptoms at day 28 (p=0.011) in one study, though results at day 84 were not statistically significant (p=0.56) 6. Other studies involving AZLI did not report specific outcome metrics for comparison 11.

Recent results — preliminary, needs further review

  • BI 1291583 was evaluated in a Phase 2 trial, but results are not yet corroborated 8.

For the clinician treating this condition

  • Azithromycin is associated with significant improvements in sputum volume and patient-reported health status scores 1.
  • Inhaled mannitol may improve quality of life (SGRQ) in patients with bronchiectasis, though it does not significantly reduce the frequency of pulmonary exacerbations 4.
  • AZLI showed early improvement in respiratory symptoms at 28 days, but this effect was not sustained at 84 days 6.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bidirectional associations exist between obstructive lung diseases and inflammatory bowel disease across 30 observational studies
Allergy & Immunology Meta-analysis
Bidirectional associations exist between obstructive lung diseases and inflammatory bowel disease across 30 observational studies Lung Disease and Inflammatory Bowel Disease Show Linked Risks
This meta-analysis of 30 observational studies identifies bidirectional associations between obstructive lung diseases (COPD, asthma, bronch…
Research shows a link between inflammatory bowel disease and several lung conditions, including asthma and COPD, suggesting these issues oft…
Frontiers Jun 30, 2026
Immediate smoking cessation support increases 12-month quit rates in adults with chronic airway diseases
Allergy & Immunology RCT
Immediate smoking cessation support increases 12-month quit rates in adults with chronic airway diseases Scheduling Quit Appointments Now Boosts Long-Term Success For Asthma Patients
This randomized trial in 397 adult smokers with asthma, COPD, or bronchiectasis compared immediate support with usual advice. The immediate …
Scheduling a quit clinic visit immediately after diagnosis doubles long-term success rates for people with asthma or COPD.
May 15, 2026
Expert consensus guidelines for N-acetylcysteine use in various respiratory conditions
Rheumatology Guideline
Expert consensus guidelines for N-acetylcysteine use in various respiratory conditions Experts share new guidance on using N-acetylcysteine for lung health
This expert consensus guideline reviews the clinical utility of N-acetylcysteine (NAC) across several respiratory diseases. The authors sugg…
Medical experts have reached a consensus on how a specific supplement might help people managing various chronic lung diseases.
Frontiers May 4, 2026
Relaxation training and early benzodiazepines linked to respiratory recovery in adults with COPD, pneumonia, asthma, bronchiectasis, or interstitial lung disease
Rheumatology Cohort
Relaxation training and early benzodiazepines linked to respiratory recovery in adults with COPD, pneumonia, asthma, bronchiectasis, or interstitial lung disease Could early sedatives be slowing down lung recovery for adults with breathing problems?
This retrospective observational study examined 389 consecutive adults (≥ 18 years) admitted with chronic obstructive pulmonary disease, pne…
Early sedatives given to adults with breathing problems may slow lung recovery, making it harder for patients to improve before leaving the …
Frontiers Apr 18, 2026
Rapamycin therapy reduced infections and lymph node size in a female child with APDS1
Rheumatology Sys. Review
Rapamycin therapy reduced infections and lymph node size in a female child with APDS1 Neck Mass Was Not Cancer, It Was This Rare Condition
This case report describes a single female patient with Activated phosphoinositide 3-kinase delta syndrome type I (APDS1) who received rapam…
A rare genetic immune disorder caused a neck mass mistaken for cancer, ending years of failed treatments for recurrent lung infections and s…
Frontiers Apr 11, 2026
Rehabilitation interventions improve functional outcomes in bronchiectasis patients, though implementation remains inconsistent across clinical settings
Physical Medicine & Rehab Guideline
Rehabilitation interventions improve functional outcomes in bronchiectasis patients, though implementation remains inconsistent across clinical settings Why is rehab for bronchiectasis recommended but hard to get?
This mini review examines contemporary evidence on rehabilitation interventions for patients with bronchiectasis.
Pulmonary rehab is a proven standard for bronchiectasis patients, yet access to these life-improving programs remains limited and inconsiste…
Frontiers Apr 6, 2026
OPEP device added to chest physiotherapy improves adherence but not clinical outcomes in children with bronchiectasis
Pediatrics RCT
OPEP device added to chest physiotherapy improves adherence but not clinical outcomes in children with bronchiectasis Adding a breathing device to chest physiotherapy improved adherence but not clinical outcomes in children with bronchiectasis
In a randomized trial of 42 children with bronchiectasis, an 8-week multicomponent chest physiotherapy program improved exercise capacity an…
Adding a breathing device to chest physiotherapy helped children stick to their routine but offered no extra lung benefits for those with br…
Apr 3, 2026

Questions about Bronchiectasis

Does adding an OPEP device to chest physiotherapy help children with bronchiectasis?

Adding an OPEP device to chest physiotherapy does not improve exercise capacity or lung function in children with bronchiectasis, but it may increase adherence to therapy.

Full answer →